Top Markets
Coin of the day
Sunny Pharmtech Inc. Sunny Pharmtech Inc.

Sunny Pharmtech Inc.

6676
Rangering i aksjer #24082
Based in Taoyuan, Taiwan, and established in 1994, Sunny Pharmtech Inc. focuses... Based in Taoyuan, Taiwan, and established in 1994, Sunny Pharmtech Inc. focuses on the entire lifecycle of pharmaceutical products, from initial research and development to manufacturing and global sales. Its operations encompass both active pharmaceutical ingredients (APIs) and finished medicinal products. The company's extensive product range includes: A lidocaine ointment, which functions as an anesthetic lubricant for intubation procedures and offers temporary relief from discomfort associated with minor burns, sunburn, skin abrasions, and insect stings. Cyanocobalamin injections, prescribed to treat vitamin B12 deficiency and pernicious anemia caused by malabsorption issues. Nitrofurantoin capsules, used in the treatment of urinary tract infections. Aminocaproic acid tablets, indicated for managing certain blood disorders and conditions involving excessive proteolytic enzyme activity. Carboprost tromethamine injections, utilized in therapeutic abortions and to address postpartum hemorrhage.
Aksjekurs
$0.38476824
Sist synkronisert: 2026-08-21
Markedsverdi
$65.29M
Endring (1 dag)
-3.20%
Endring (1 år)
-40.81%
Land
TW
Handel Sunny Pharmtech Inc. (6676)

Kategori

Inntekter for Sunny Pharmtech Inc. (6676)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Sunny Pharmtech Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Sunny Pharmtech Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.70B -
AU
- -
CH